In the Claims:

Please amend claims 1, 16, 18-19 and 41. Please cancel claims 9, 14 and 15. Please add new claims 42 and 43.

1. (Currently Amended) A compound of formula (I):



wherein:

a is 1-5;

each R^1 is the same or different and is independently selected from the group consisting of halo, alkyl, alkenyl, $-OR^6$, $-S(O)_fR^6$, $-NR^6R^7$, $-R^4OR^6$, $-R^4S(O)_fR^6$, $-R^4NR^6R^7$ and cyano;

b is 0-3;

R^2 is selected from the group consisting of alkyl, alkenyl, C_{3-6}cycloalkyl, C_{3-6}cycloalkenyl, $-OR^6$, $-NR^6R^7$, $-R^4OR^6$, $-R^4NR^6R^7$, cyano and nitro;

Y is -O- or $-N(R^8)-$;

c is 0-4;

each R^3 is the same or different and is independently selected from the group consisting of halo, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, $-OR^6$, $-COR^6$, $-CO_2R^6$, $-CH(R^6)OR^7$, $-S(O)_fR^6$, $-NR^6R^7$, $-R^4$cycloalkyl, $-R^4OR^6$, $-R^4COR^6$, $-R^4CO_2R^6$, $-R^4S(O)_fR^6$, $-R^4NR^6R^7$ and cyano;

Z is selected from the group consisting of $-O-R^4-$, ~~$-R^4-O-$~~, $-S(O)_fR^4-$, ~~$-R^4-S(O)_f-$~~, $-N(R^8)-R^4-$, $-R^4-N(R^8)-$, ~~$-C(O)N(R^8)-$~~, $-C(O)R^4N(R^8)-$, $-S(O)_fN(R^8)-$ and $-S(O)_fR^4N(R^8)-$;

each R^4 is the same or different and is independently selected from the group consisting of alkylene and alkenylene;

R^5 is selected from the group consisting of R^6O-, R^6O_2C-, and



wherein Ring A is aryl or a 5-12 membered heterocycle or heteroaryl;

d is 0-4;

each R^9 is the same or different and is independently selected from the group consisting of halo, alkyl, alkenyl, alkynyl, cycloalkyl, $-OR^6$, $-COR^6$, $-CO_2R^6$, $-CH(R^6)OR^7$, $-S(O)_fR^6$, $-NR^6R^7$, $-R^4$cycloalkyl, $-R^4OR^6$, $-R^4COR^6$, $-R^4CO_2R^6$, $-R^4S(O)_fR^6$, $-R^4NR^6R^7$, cyano, 5-9 membered heterocycle and 5-9 membered heteroaryl;

each R^6 and R^7 are the same or different and are each independently selected from the group consisting of H, alkyl, alkenyl, C_{3-6}cycloalkyl and C_{3-6}cycolalkenyl;

R^8 is H or alkyl; and

each f is the same or different and is independently selected from the group consisting of 0, 1 and 2;

or a pharmaceutically acceptable salt, or solvate ~~or physiologically functional derivative~~ thereof.

2. (Original) The compound according to claim 1 wherein a is 1-2.

3. (Previously Presented) The compound according to claim 1 wherein each R^1 is the same or different and is independently selected from the group consisting of halo and $-OR^6$.

4. (Previously Presented) The compound according to claim 1 wherein b is 0 or 1.

5. (Previously Presented) The compound according to claim 1 wherein R^2 is selected from the group consisting of alkyl and C_{3-6}cycloalkyl.

6. (Previously Presented) The compound according to claim 1 wherein Y is -O-.

7. (Previously Presented) The compound according claim 1, wherein c is 0-2.

8. (Previously Presented) The compound according to claim 1, wherein each R^3 is the same or different and is independently selected from the group consisting of halo and alkyl.

9. (Cancelled)

10. (Previously Presented) The compound according to claim 1, wherein R^8 is H or methyl.

11. (Previously Presented) The compound according to claim 1, wherein R^5 is selected from the group consisting of R^6O_2C-, and  .

12. (Previously Presented) The compound according to claim 1, wherein R^5 is and Ring A is phenyl or furan.

13. (Currently Amended) A pharmaceutical composition comprising a compound according to claim 1 and a pharmaceutically acceptable carrier or diluent.

14. (Cancelled)

15. (Cancelled)

16. (Currently Amended) A method for the treatment ~~or prophylaxis~~ of cardiovascular disease in a subject, said method comprising administering to said subject a therapeutically effective amount of a compound according to claim 1.

17. (Original) The method according to claim 16, wherein said cardiovascular disease is selected from atherosclerosis and hypercholesterolemia.

18. (Currently Amended) A method for the treatment ~~or prophylaxis~~ of cholestatic liver disease in a subject comprising administering a therapeutically effective amount of a compound according to claim 1.

19. (Currently Amended) A method for the treatment ~~or prophylaxis of~~ organ fibrosis in a subject comprising administering a therapeutically effective amount of a compound according to claim 1.

20. (Previously Presented) A method for increasing HDL cholesterol in a subject, said method comprising administering a therapeutically effective amount of a compound according to claim 1.

21. (Previously Presented) A method for lowering triglycerides in a subject, said method comprising administering a therapeutically effective amount of a compound according to claim 1.

22. (Previously Presented) A process for preparing a compound according to claim 1, said process comprising the steps of:

a) reducing a compound of formula (X):



X

followed by chorination to prepare a compound of formula (XI):



XI

and

b) reacting the compound of formula (XI) with a compound of formula (XII):

$$R^5—Z^1 \qquad XII$$

wherein Z^1 is -O-, -S(O)$_f$- or -N(R^8)-;

to prepare a compound of formula (I-A):



I-A

23. (Previously Presented) A process for preparing a compound according to claim 1, said process comprising the steps of:

a) rearranging the carbonyl functionality of the compound of formula (X):



X

followed by hydrolysis to prepare a compound of formula (XIII):



XIII

and

b) reacting the compound of formula (XIII) with a suitable electrophile to prepare a compound of formula (I-B):



I-B

wherein Z^2 is $-R^4-O-$.

24. (Previously Presented) A process for preparing a compound according to claim 1, said process comprising the steps of:

a) reacting a protected compound of formula (XV):



XV

wherein PG is a protecting group;

with a compound of formula (VI):



VI

to prepare a compound of formula (XVI):



XVI

b) optionally alkylating the compound of formula (XVI), followed by deprotecting the compound of formula (XVI) to prepare a compound of formula (XVII):



XVII

and

c) reacting the compound of formula (XVII) with a suitable electrophile to prepare a compound of formula (I-C):



I-C

wherein Z^3 is selected from the group consisting of $-R^4-O-$, $-R^4-S(O)_f-$, $-R^4-N(R^8)-$, $-CON(R^8)-$, $-C(O)R^4N(R^8)-$, $-S(O)_fN(R^8)-$ and $-S(O)_fR^4N(R^8)-$.

25-40. (Cancelled)

41. (Currently Amended) A compound selected from:

3-{[(4-{[3-(2,6-Dichlorophenyl)-5-isopropylisoxazol-4-yl]methoxy}-2-methylphenyl)-(methyl)amino]methyl}benzoic acid;

Methyl 4-[(4-{[3-(2,6-dichlorophenyl)-5-isopropyl-4-isoxazolyl]methoxy}-2-dimethylanilino)methyl]benzoate;

3-{[(2-Chloro-4-{[3-(2,6-dichlorophenyl)-5-isopropylisoxazol-4-yl]methoxy}-phenyl)amino]methyl}benzoic acid;

5-[(4-{[3-(2,6-Dichlorophenyl)-5-isopropyl-4-isoxazolyl]methoxy}-2-dimethyl-anilino)methyl]-2-furoic acid;

4-[(4-{[3-(2,6-Dichlorophenyl)-5-isopropyl-4-isoxazolyl]methoxy}-2-dimethyl-anilino)methyl]benzoic acid;

Methyl 2-[(4-{[3-(2,6-dichlorophenyl)-5-isopropyl-4-isoxazolyl]methoxy}-2-dimethylanilino)methyl]-3-furoate;

N-(2,1,3-Benzoxadiazol-5-ylmethyl)-4-{[3-(2,6-dichlorophenyl)-5-isopropyl-4-isoxazolyl]methoxy}-*N*,2-dimethylaniline;

N-(4-{[3-(2,6-Dichlorophenyl)-5-isopropyl-4-isoxazolyl]methoxy}-2-methylphenyl)-*N*-methyl-*N*-[4-(1,2,3-thiadiazol-4-yl)benzyl]amine;

4-[(4-{[3-(2,6-Dichlorophenyl)-5-isopropyl-4-isoxazolyl]methoxy}-2-dimethyl-anilino)methyl]benzonitrile;

2-[(4-{[3-(2,6-Dichlorophenyl)-5-isopropyl-4-isoxazolyl]methoxy}-2-dimethyl-anilino)methyl]-3-furoic acid;

{3-[(4-{[3-(2,6-Dichlorophenyl)-5-isopropyl-4-isoxazolyl]methoxy}-2-dimethylanilino)methyl]phenyl}methanol;

{4-[(4-{[3-(2,6-Dichlorophenyl)-5-isopropyl-4-isoxazolyl]methoxy}-2-dimethylanilino)methyl]phenyl}methanol;

3-[(4-{[3-(2,6-Dichlorobenzyl)-5-ethyl-4-isoxazolyl]methoxy}-2-dimethylanilino)methyl]benzoic acid;

3-{[(4-{[5-Isopropyl-3-(2,4,6-trichlorophenyl)isoxazol-4-yl]methoxy}-2-methylphenyl)-(methyl)amino]methyl}benzoic acid;

3-[(4-{[3-(2,6-Dichlorobenzyl)-5-isopropyl-4-isoxazolyl]methoxy}-2-dimethylanilino)methyl]benzoic acid;

3-{[(4-{[3-(2-Chlorobenzyl)-5-isopropylisoxazol-4-yl]methoxy}-2-methylphenyl)-(methyl)-amino]methyl}benzoic acid;

3-[(4-{[5-Cyclopropyl-3-(2,6-dichlorobenzyl)-4-isoxazolyl]methoxy}-2-dimethylanilino)methyl]benzoic acid;

5-{[4-({5-Isopropyl-3-[2-(trifluoromethoxy)phenyl]-4-isoxazolyl}methoxy)-2-dimethylanilino]methyl}-2-furoic acid;

4-{[4-({5-Isopropyl-3-[2-(trifluoromethoxy)phenyl]-4-isoxazolyl}methoxy)-2-dimethylanilino]methyl}benzoic acid;

3-{[4-({5-Isopropyl-3-[2-(trifluoromethoxy)phenyl]-4-isoxazolyl}methoxy)-2-dimethylanilino]methyl}benzoic acid;

Methyl 5-{[4-({5-isopropyl-3-[2-(trifluoromethoxy)phenyl]-4-isoxazolyl}methoxy)-2-dimethylanilino]methyl}-2-furoate;

Methyl 4-{[4-({5-isopropyl-3-[2-(trifluoromethoxy)phenyl]-4-isoxazolyl}methoxy)-2-dimethylanilino]methyl}benzoate;

4-{[(2-Chloro-4-{[3-(2,6-dichlorophenyl)-5-isopropylisoxazol-4-yl]methoxy}phenyl)-amino]carbonyl}benzoic acid;

Methyl 3-[(2-chloro-4-{[3-(2,6-dichlorophenyl)-5-isopropyl-4-isoxazolyl]methoxy}-anilino)carbonyl]benzoate;

Methyl 4-[(2-chloro-4-{[3-(2,6-dichlorophenyl)-5-isopropyl-4-isoxazolyl]methoxy}-anilino)carbonyl]benzoate;

3-[(4-{[3-(2,6-Dichlorophenyl)-5-isopropyl-4-isoxazolyl]methoxy}-2-methylanilino)-carbonyl]benzoic acid;

4-[(4-{[3-(2,6-Dichlorophenyl)-5-isopropyl-4-isoxazolyl]methoxy}-2-methylanilino)-carbonyl]benzoic acid;

3-[(2-Chloro-4-{[3-(2,6-dichlorophenyl)-5-isopropyl-4-isoxazolyl]methoxy}-anilino)carbonyl]benzoic acid;

3-[(4-{[3-(2,6-Dichlorophenyl)-5-isopropyl-4-isoxazolyl]methoxy}-2-dimethylanilino)carbonyl]benzoic acid;

3-[(2-Chloro-4-{[3-(2,6-dichlorophenyl)-5-isopropyl-4-isoxazolyl]methoxy}-methylanilino)carbonyl]benzoic acid;

4-[(2-Chloro-4-{[3-(2,6-dichlorophenyl)-5-isopropyl-4-isoxazolyl]methoxy}-methylanilino)carbonyl]benzoic acid;

3-{[4-({5-Isopropyl-3-[2-(trifluoromethoxy)phenyl]-4-isoxazolyl}methoxy)-2-dimethylanilino]carbonyl}benzoic acid;

3-{[4-({5-Isopropyl-3-[2-(trifluoromethoxy)phenyl]-4-isoxazolyl}methoxy)-2-methylanilino]carbonyl}benzoic acid;

3-{[2-Chloro-4-({5-isopropyl-3-[2-(trifluoromethoxy)phenyl]-4-isoxazolyl}-methoxy)methylanilino]carbonyl}benzoic acid;

Methyl 3-{[(4-{[3-(2,6-dichlorophenyl)-5-isopropylisoxazol-4-yl]methoxy}-2-methylphenyl)(methyl)amino]sulfonyl}benzoate;

Methyl 3-{[(2-chloro-4-{[3-(2,6-dichlorophenyl)-5-isopropylisoxazol-4-yl]methoxy}-phenyl)amino]sulfonyl}benzoate;

Methyl 3-{[(4-{[3-(2,6-dichlorophenyl)-5-isopropylisoxazol-4-yl]methoxy}-2-methylphenyl)amino]sulfonyl}benzoate;

Methyl 3-{[(4-{[3-(2,6-dichlorophenyl)-5-isopropylisoxazol-4 yl]methoxy}phenyl)-amino]- sulfonyl}benzoate;

3-{[(4-{[3-(2,6-Dichlorophenyl)-5-isopropylisoxazol-4-yl]methoxy}-2-methylphenyl)-amino]sulfonyl}benzoic acid;

3-{[(4-{[3-(2,6-Dichlorophenyl)-5-isopropylisoxazol-4-yl]methoxy}phenyl)amino]-sulfonyl}benzoic acid;

Methyl 3-{[(2-chloro-4-{[3-(2,6-dichlorophenyl)-5-isopropylisoxazol-4-yl]methoxy}-phenyl)(methyl)amino]sulfonyl}benzoate;

Methyl 3-{[(4-{[3-(2,6-dichlorophenyl)-5-isopropylisoxazol-4-yl]methoxy}phenyl)-(methyl)amino]sulfonyl}benzoate;

Methyl 3-{[(2-chloro-4-{[3-(2,6-dichlorophenyl)-5-isopropylisoxazol-4-yl]methoxy}-phenyl)(ethyl)amino]sulfonyl}benzoate;

Methyl 3-{[(4-{[3-(2,6-dichlorophenyl)-5-isopropylisoxazol-4-yl]methoxy}-2-methyl-phenyl)(ethyl)amino]sulfonyl}benzoate;

Methyl 3-{[(4-{[3-(2,6-dichlorophenyl)-5-isopropylisoxazol-4-yl]methoxy}phenyl)-(ethyl)-amino]sulfonyl}benzoate;

3-{[(2-Chloro-4-{[3-(2,6-dichlorophenyl)-5-isopropylisoxazol-4-yl]methoxy}phenyl)-amino]sulfonyl}benzoic acid;

3-{[(2-Chloro-4-{[3-(2,6-dichlorophenyl)-5-isopropylisoxazol-4-yl]methoxy}phenyl)-(methyl)amino]sulfonyl}benzoic acid;

3-{[(4-{[3-(2,6-Dichlorophenyl)-5-isopropylisoxazol-4-yl]methoxy}-2-methylphenyl)-(methyl)amino]sulfonyl}benzoic acid;

3-{[(4-{[3-(2,6-Dichlorophenyl)-5-isopropylisoxazol-4-yl]methoxy}phenyl)(methyl)-amino]sulfonyl}benzoic acid;

3-{[(2-Chloro-4-{[3-(2,6-dichlorophenyl)-5-isopropylisoxazol-4-yl]methoxy}phenyl)-(ethyl)amino]sulfonyl}benzoic acid;

3-{[(4-{[3-(2,6-Dichlorophenyl)-5-isopropylisoxazol-4-yl]methoxy}-2-methylphenyl)-(ethyl)amino]sulfonyl}benzoic acid;

3-{[(4-{[3-(2,6-Dichlorophenyl)-5-isopropylisoxazol-4-yl]methoxy}phenyl)(ethyl)-amino]sulfonyl}benzoic acid;

Methyl 4-{[(2-chloro-4-{[3-(2,6-dichlorophenyl)-5-isopropylisoxazol-4-yl]methoxy}-phenyl)amino]sulfonyl}benzoate;

Methyl 4-{[(4-{[3-(2,6-dichlorophenyl)-5-isopropylisoxazol-4-yl]methoxy}-2-methyl-phenyl)amino]sulfonyl}benzoate;

Methyl 4-{[(4-{[3-(2,6-dichlorophenyl)-5-isopropylisoxazol-4-yl]methoxy}phenyl)-amino]sulfonyl}benzoate;

4-{[(2-Chloro-4-{[3-(2,6-dichlorophenyl)-5-isopropylisoxazol-4-yl]methoxy}phenyl)-amino]sulfonyl}benzoic acid;

4-{[(4-{[3-(2,6-Dichlorophenyl)-5-isopropylisoxazol-4-yl]methoxy}-2-methylphenyl)-amino]sulfonyl}benzoic acid;

4-{[(4-{[3-(2,6-Dichlorophenyl)-5-isopropylisoxazol-4-yl]methoxy}phenyl)amino]-sulfonyl}benzoic acid;

Methyl 4-{[(4-{[3-(2,6-dichlorophenyl)-5-isopropylisoxazol-4-yl]methoxy}-2-methyl-phenyl)(methyl)amino]sulfonyl}benzoate;

Methyl 4-{[(4-{[3-(2,6-dichlorophenyl)-5-isopropylisoxazol-4-yl]methoxy}phenyl)-(methyl)amino]sulfonyl}benzoate;

Methyl 4-{[(4-{[3-(2,6-dichlorophenyl)-5-isopropylisoxazol-4-yl]methoxy}phenyl)-(ethyl)amino]sulfonyl}benzoate;

4-{[(2-Chloro-4-{[3-(2,6-dichlorophenyl)-5-isopropylisoxazol-4-yl]methoxy}phenyl)-(methyl)amino]sulfonyl}benzoic acid;

4-{[(4-{[3-(2,6-Dichlorophenyl)-5-isopropylisoxazol-4-yl]methoxy}-2-methylphenyl)-(methyl)amino]sulfonyl}benzoic acid;

4-{[(4-{[3-(2,6-Dichlorophenyl)-5-isopropylisoxazol-4-yl]methoxy}phenyl)(methyl)-amino]sulfonyl}benzoic acid;

4-{[(2-Chloro-4-{[3-(2,6-dichlorophenyl)-5-isopropylisoxazol-4-yl]methoxy}phenyl)-(ethyl)amino]sulfonyl}benzoic acid;

4-{[(4-{[3-(2,6-Dichlorophenyl)-5-isopropylisoxazol-4-yl]methoxy}-2-methylphenyl)-(ethyl)amino]sulfonyl}benzoic acid;

4-{[(4-{[3-(2,6-Dichlorophenyl)-5-isopropylisoxazol-4-yl]methoxy}phenyl)(ethyl)amino]-sulfonyl}benzoic acid;

3-({[2-Chloro-4-({5-isopropyl-3-[2-(trifluoromethoxy)phenyl]isoxazol-4-yl}methoxy)-phenyl]amino}sulfonyl)benzoic acid;

3-({[4-({5-Isopropyl-3-[2-(trifluoromethoxy)phenyl]isoxazol-4-yl}methoxy)-2-methyl-phenyl]amino}sulfonyl)benzoic acid;

Methyl 3-{[[2-chloro-4-({5-isopropyl-3-[2-(trifluoromethoxy)phenyl]-isoxazol-4-yl}methoxy)phenyl](methyl)amino]sulfonyl}benzoate;

Methyl 3-{[[4-({5-isopropyl-3-[2-(trifluoromethoxy)phenyl]isoxazol-4-yl}methoxy)-2-methylphenyl](methyl)amino]sulfonyl}benzoate;

3-{[[2-Chloro-4-({5-isopropyl-3-[2-(trifluoromethoxy)phenyl]isoxazol-4-yl}methoxy)-phenyl](methyl)amino]sulfonyl}benzoic acid;

3-{[[4-({5-Isopropyl-3-[2-(trifluoromethoxy)phenyl]isoxazol-4-yl}methoxy)-2-methyl-phenyl](methyl)amino]sulfonyl}benzoic acid;

3-{[(4-{[3-(2,6-Dichlorobenzyl)-5-ethylisoxazol-4-yl]methoxy}-2-methylphenyl)(methyl)-amino]sulfonyl}benzoic acid;

Methyl 4-[(2-chloro-4-{[3-(2,6-dichlorophenyl)-5-isopropylisoxazol-4-yl]methoxy}-benzyl)oxy]benzoate;

Methyl 3-[(2-chloro-4-{[3-(2,6-dichlorophenyl)-5-isopropylisoxazol-4-yl]methoxy}-benzyl)-oxy]benzoate;

3-[(2-Chloro-4-{[3-(2,6-dichlorophenyl)-5-isopropylisoxazol-4-yl]methoxy}-benzyl)oxy]-benzoic acid;

3-[(2-Chloro-4-{[3-(2,6-dichlorophenyl)-5-isopropylisoxazol-4-yl]methoxy}-benzyl)thio]-benzoic acid;

3-[(4-{[3-(2,6-Dichlorophenyl)-5-isopropylisoxazol-4-yl]methoxy}-2-methylbenzyl)-oxy]-benzoic acid;

3-[(4-{[3-(2,6-Dichlorophenyl)-5-isopropylisoxazol-4-yl]methoxy}-2-methylbenzyl)-thio]-benzoic acid;

4-[(2-Chloro-4-{[3-(2,6-dichlorophenyl)-5-isopropylisoxazol-4-yl]methoxy}benzyl)-oxy]benzoic acid;

4-[(2-Chloro-4-{[3-(2,6-dichlorophenyl)-5-isopropylisoxazol-4-yl]methoxy}benzyl)-thio]-benzoic acid;

Methyl 3-{[2-chloro-4-({5-isopropyl-3-[2-(trifluoromethoxy)-phenyl]isoxazol-4-yl}methoxy)benzyl]oxy}benzoate;

Methyl 3-{[4-({5-isopropyl-3-[2-(trifluoromethoxy)phenyl]isoxazol-4-yl}methoxy)-2-methylbenzyl]oxy}benzoate;

3-{[2-Chloro-4-({5-isopropyl-3-[2-(trifluoromethoxy)phenyl]isoxazol-4-yl}methoxy)-benzyl]oxy}benzoic acid;

3-{[4-({5-Isopropyl-3-[2-(trifluoromethoxy)phenyl]isoxazol-4-yl}methoxy)-2-methyl-benzyl]oxy}benzoic acid;

3-[(2-Chloro-4-{[3-(2,6-dichlorobenzyl)-5-ethylisoxazol-4-yl]methoxy}benzyl)oxy]-benzoic acid;

Methyl 3-{[2-chloro-4-({5-isopropyl-3-[2-(trifluoro-methoxy)phenyl]isoxazol-4-yl}methoxy)benzyl]thio}benzoate;

Methyl 3-{[4-({5-isopropyl-3-[2-(trifluoromethoxy)phenyl]isoxazol-4-yl}methoxy)-2-methylbenzyl]thio}benzoate;

3-{[2-Chloro-4-({5-isopropyl-3-[2-(trifluoromethoxy)phenyl]isoxazol-4-yl}methoxy)-benzyl]thio}benzoic acid;

3-{[4-({5-Isopropyl-3-[2-(trifluoromethoxy)phenyl]isoxazol-4-yl}methoxy)-2-methyl-benzyl]thio}benzoic acid;

Methyl 3-[(2-chloro-4-{[3-(2,6-dichlorophenyl)-5-isopropylisoxazol-4-yl]methoxy}benzyl)(methyl)amino]benzoate;

3-[(2-Chloro-4-{[3-(2,6-dichlorophenyl)-5-isopropylisoxazol-4-yl]methoxy}benzyl)-(methyl)amino]benzoic acid;

3-[(2-Chloro-4-{[3-(2,6-dichlorophenyl)-5-isopropylisoxazol-4-yl]methoxy}benzyl)-amino]benzoic acid;

Ethyl 3-{[2-chloro-4-({5-isopropyl-3-[2-(trifluoromethoxy)phenyl]-4-isoxazolyl}-methoxy)benzyl]amino}benzoate;

3-{[2-Chloro-4-({5-isopropyl-3-[2-(trifluoromethoxy)phenyl]-4-isoxazolyl}methoxy)-benzyl]amino}benzoic acid;

3-[[2-Chloro-4-({5-isopropyl-3-[2-(trifluoromethoxy)phenyl]-4-isoxazolyl}methoxy)-benzyl](methyl)amino]benzoic acid;

Methyl 4-[(4-{[3-(2,6-dichlorophenyl)-5-isopropylisoxazol-4-yl]methoxy}-2-methylphenoxy)methyl]benzoate;

Methyl 3-[(2-chloro-4-{[3-(2,6-dichlorophenyl)-5-isopropylisoxazol-4-yl]methoxy}-phenoxy)methyl]benzoate;

Methyl 3-[(4-{[3-(2,6-dichlorophenyl)-5-isopropylisoxazol-4-yl]methoxy}-2-methyl-phenoxy)methyl]benzoate;

3-[(2-Chloro-4-{[3-(2,6-dichlorophenyl)-5-isopropylisoxazol-4-yl]methoxy}phenoxy)-methyl]benzoic acid;

3-[(4-{[3-(2,6-Dichlorophenyl)-5-isopropylisoxazol-4-yl]methoxy}-2-methylphenoxy)-methyl]benzoic acid; and

Methyl 4-[(4-{[3-(2,6-dichlorophenyl)-5-isopropylisoxazol-4-yl]methoxy}-2-methyl-phenoxy)methyl]benzoate,

and pharmaceutically acceptable salts~~,~~ and solvates ~~and physiologically functional derivatives~~ thereof.

42. (New) A compound of formula (I):



I

wherein:

a is 1-5;

each R^1 is the same or different and is independently selected from the group consisting of halo, alkyl, alkenyl, $-OR^6$, $-S(O)_fR^6$, $-NR^6R^7$, $-R^4OR^6$, $-R^4S(O)_fR^6$, $-R^4NR^6R^7$ and cyano;

b is 0-3;

R^2 is selected from the group consisting of alkyl, alkenyl, C_{3-6}cycloalkyl, C_{3-6}cycloalkenyl, $-OR^6$, $-NR^6R^7$, $-R^4OR^6$, $-R^4NR^6R^7$, cyano and nitro;

Y is -O- or $-N(R^8)$-;

c is 0-4;

each R^3 is the same or different and is independently selected from the group consisting of halo, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, $-OR^6$, $-COR^6$, $-CO_2R^6$, $-CH(R^6)OR^7$, $-S(O)_fR^6$, $-NR^6R^7$, $-R^4$cycloalkyl, $-R^4OR^6$, $-R^4COR^6$, $-R^4CO_2R^6$, $-R^4S(O)_fR^6$, $-R^4NR^6R^7$ and cyano;

Z is $-C(O)N(R^8)-$;

each R^4 is the same or different and is independently selected from the group consisting of alkylene and alkenylene;

R^5 is selected from the group consisting of R^6O_2C- and



wherein Ring A is aryl or a 5-12 membered heterocycle or heteroaryl;

d is 0-4;

each R^9 is the same or different and is independently selected from the group consisting of halo, alkyl, alkenyl, alkynyl, cycloalkyl, $-OR^6$, $-COR^6$, $-CO_2R^6$, $-CH(R^6)OR^7$, $-S(O)_fR^6$, $-NR^6R^7$, $-R^4$cycloalkyl, $-R^4OR^6$, $-R^4COR^6$, $-R^4CO_2R^6$, $-R^4S(O)_fR^6$, $-R^4NR^6R^7$, cyano, 5-9 membered heterocycle and 5-9 membered heteroaryl;

each R^6 and R^7 are the same or different and are each independently selected from the group consisting of H, alkyl, alkenyl, C_{3-6}cycloalkyl and C_{3-6}cycolalkenyl;

R^8 is H or alkyl; and

each f is the same or different and is independently selected from the group consisting of 0, 1 and 2;

or a pharmaceutically acceptable salt or solvate thereof.

43. (New) A compound of formula (I):



I

wherein:

a is 1-5;

each R^1 is the same or different and is independently selected from the group consisting of halo, alkyl, alkenyl, $-OR^6$, $-S(O)_fR^6$, $-NR^6R^7$, $-R^4OR^6$, $-R^4S(O)_fR^6$, $-R^4NR^6R^7$ and cyano;

b is 0-3;

R^2 is selected from the group consisting of alkyl, alkenyl, C_{3-6}cycloalkyl, C_{3-6}cycloalkenyl, $-OR^6$, $-NR^6R^7$, $-R^4OR^6$, $-R^4NR^6R^7$, cyano and nitro;

Y is -O- or $-N(R^8)-$;

c is 0-4;

each R^3 is the same or different and is independently selected from the group consisting of halo, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, $-OR^6$, $-COR^6$, $-CO_2R^6$, $-CH(R^6)OR^7$, $-S(O)_fR^6$, $-NR^6R^7$, $-R^4$cycloalkyl, $-R^4OR^6$, $-R^4COR^6$, $-R^4CO_2R^6$, $-R^4S(O)_fR^6$, $-R^4NR^6R^7$ and cyano;

Z is $-R^4-O-$;

each R^4 is the same or different and is independently selected from the group consisting of alkylene and alkenylene;

R^5 is



wherein Ring A is aryl or a 5-12 membered heterocycle or heteroaryl;

d is 0-4;

each R^9 is the same or different and is independently selected from the group consisting of halo, alkyl, alkenyl, alkynyl, cycloalkyl, $-OR^6$, $-COR^6$, $-CO_2R^6$, $-CH(R^6)OR^7$, $-S(O)_fR^6$, $-NR^6R^7$, $-R^4$cycloalkyl, $-R^4OR^6$, $-R^4COR^6$, $-R^4CO_2R^6$, $-R^4S(O)_fR^6$, $-R^4NR^6R^7$, cyano, 5-9 membered heterocycle and 5-9 membered heteroaryl;

each R^6 and R^7 are the same or different and are each independently selected from the group consisting of H, alkyl, alkenyl, C_{3-6}cycloalkyl and C_{3-6}cycolalkenyl;

R^8 is H or alkyl; and

each f is the same or different and is independently selected from the group consisting of 0, 1 and 2;

or a pharmaceutically acceptable salt or solvate thereof.